Outsourcing Pharma

DECEMBER 21, 2020

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

Immunity 96

Immunity Immunization Drug Development 96

STAT

APRIL 10, 2024

The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.

Vaccines 364

Vaccines Immunity Immunization Drug Development 364

STAT

NOVEMBER 28, 2023

The negative study, called ADVANCE-SC, was the second of two clinical trials involving the Argenx drug called efgartigimod in patients with primary immune thrombocytopenia (ITP), a debilitating condition that destroys blood-clotting platelets. Argenx shares were down 12% in early trading.

Immunity 323

Immunity Immunization Drug Development 323

STAT

SEPTEMBER 26, 2023

Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.

Immunity 339

Immunity Immunization Drug Development 339

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.

Immunity 103

Immunity Immunization Drug Development 103

pharmaphorum

NOVEMBER 1, 2024

The 8th Antigen-Specific Immune Tolerance Drug Development Summit is an event organised by Hanson Wade. Discover the latest developments and networking opportunities at this leading industry conference.

Immunity 52

Immunity Immunization Drug Development 52

BioPharma Dive

JUNE 20, 2023

The deal adds to recent M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.

Immunity 95

Immunity Immunization Drug Development 95

STAT

MARCH 28, 2024

Today, we’re reading about the world’s costliest drug, plus we learn about immune senescence and a potential cause for a kidney autoimmune disease. Sign up to get it in your inbox here. It’s Meghana. Read the rest…

Immunity 280

Immunity Immunization Drug Pricing Drug Development 280

World Pharma News

MAY 23, 2023

Jude Children’s Research Hospital and the University of Texas Southwestern Medical Center studied the structure and function of a transporter involved in cancer and immunity. The findings, published in Cell, have implications for drug development.

Drug Development 84

Drug Development Immunity Immunization Hospitals 84

STAT

MAY 16, 2024

The need-to-know this morning Biogen  and  Ionis Pharmaceuticals  are  ending their development  of an experimental drug for ALS based on results of a Phase 1/2 trial. Novartis  said it’s  met all tender offer conditions  to acquire German biotech Morphosys.

Immunity 273

Immunity Immunization Drug Pricing Drug Development 273

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunity Immunization 98

BioPharma Dive

MARCH 25, 2024

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Immunity 65

Immunity Immunization Drug Development 65

BioPharma Dive

AUGUST 22, 2023

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Immunity 98

Immunity Immunization Drug Development 98

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Drug Development 105

Drug Development Communication Immunity Immunization 105

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drug development forum.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Drug Development 98

Drug Development Communication Immunity Immunization 98

STAT

OCTOBER 24, 2024

Among the basic and life-saving medicines for which shortages continue to be problematic are Rho(D) immune globulin, pain and sedation medications, and ADHD pills. So far this year, 95 new shortages were reported, a drop from 156 in 2023, although 50% of active shortages have persisted for two or more years.

Immunity 265

Immunity Immunization Drug Pricing Drug Development 265

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Register for your FREE ticket here: [link].

Drug Development 52

Drug Development Immunity Immunization 52

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immunity 115

Immunity Immunization Drug Development 115

pharmaphorum

APRIL 20, 2021

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. The post Non-Small Cell Lung Cancer Drug Development Summit appeared first on. View the event guide now for more details!

Drug Development 52

Drug Development Medical Schools Immunity Immunization 52

European Pharmaceutical Review

MAY 14, 2024

Takeda and AC Immune SA have agreed a global option and license agreement for a potential first-in-class Abeta-targeting active immunotherapy for Alzheimer’s. AC Immune’s related immunotherapies targeting Abeta are part of the deal, including the Alzheimer’s treatment ACI-24.060.

Immunity 97

Immunity Immunization Drug Development 97

BioPharma Dive

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development 57

Drug Development Immunity Immunization 57

Pharmaceutical Technology

APRIL 5, 2023

Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development. Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses.

Drug Development 52

Drug Development Immunity Immunization 52

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunity 105

Immunity Immunization Drug Development 105

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunity 65

Immunity Immunization Drug Development 65

BioPharma Dive

OCTOBER 31, 2024

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.

Immunity 61

Immunity Immunization Drug Development 61

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunity 61

Immunity Immunization Drug Development 61

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

NOVEMBER 30, 2020

As AAV is a virus derived from the common cold, the immune system can easily have levels of pre-existing NAbs that will recognise and neutralise AAV, rendering it ineffective. In serious cases, higher levels of pre-existing NAbs can even cause a dangerous immune reaction when such therapies are administered.

Immunity 105

Immunity Immunization Drug Development 105

Pharmaceutical Technology

JUNE 12, 2023

CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells. As drug targets, these receptors have demonstrated therapeutic value against different pain varieties. However, along with other painkiller alternatives, doubts have been cast over their efficacy.

Immunity 143

Immunity Immunization Drug Development 143

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). The acceptance of the IND application for SM17 not only accelerated the company’s clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. “It

Immunity 109

Immunity Immunization Drug Development 109

European Pharmaceutical Review

AUGUST 9, 2023

As a highly selective BTK inhibitor, remibrutinib “has the potential to be a first-in-class, oral treatment for people living with CSU whose symptoms are refractory despite use of antihistamines,” stated Dr Shreeram Aradhye, President of Global Drug Development and Chief Medical Officer at Novartis.

Immunity 94

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 94

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Immunization 97

Immunization Immunity Hospitals Drug Development 97

pharmaphorum

APRIL 12, 2021

This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunity 52

Immunity Immunization Drug Development 52

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds.

Compounding 105

Compounding Immunity Immunization Drug Development 105

pharmaphorum

OCTOBER 6, 2022

As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissues form the tumour micro-environment (TME).

Immunity 52

Immunity Immunization Drug Development 52

pharmaphorum

APRIL 26, 2022

As more research has been conducted, closer and unexpected links have been found between the microbiome of the gut, as one example, and other areas of the body, such as brain health and the immune system. Compelling advantages.

Immunity 115

Immunity Immunization Diabetes Drug Development 115